Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

InO - A Retrospective Study of UK Patients With Leukaemia
InO - A Retrospective Study of UK Patients With Leukaemia

NCT04456959

CompletedN/A

Sponsor: Pfizer

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Inotuzumab Ozogamicin

Countries: United Kingdom

The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Patients with relapsed/refractory ALL.
* Patients who initiated InO between 1st of June 2016 and date of data collection.
* Patients who accessed InO treatment via NHS commissioning, via the CUP, or via private purchase.
* Patient aged ≥18 years old at initiation of InO treatment

Exclusion Criteria:

* Patients initiated on treatment with InO at a different hospital than the ones selected in this study.
* Patients with \<3 months of follow-up since index date, unless death occurs \<3 months from index date.
Locations (4)
  • Bristol, United Kingdom
  • London, United Kingdom
  • London, United Kingdom
  • Taunton, United Kingdom